[Published] 2020/3/18 [Last updated] 2020/3/18

Presentations for International Conferences

DatePresenterName of ConferenceStyle of PresentationTitleCityCountry
2019 Mar 16S. Kitano2019 Annual Meeting of Taiwan Surgical Association/Tiwan Oncology SocietyOral presentationClinical Development of Gene Transferred T Cell TherapyTaipei Taiwan
2019 Feb 28S. Kitano2019 ASCO-SITC Clinical Immunooncology SymposiumPoster presentationPhase 1 Study of Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Japanese Patients with Advanced Malignancies: Results from the Dose Exploration San FranciscoUnited States
2019 Feb 26J. SatoTargeted Anticancer Therapies 2019Oral presentationDynamic Change in the distribution of cancer types in oncology phase I trialsParisFrance
2018 Dec 5K. Yonemori41st Annual San Antonio Breast Cancer SymposiumPoster presentationLong-term follow-up of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial) comparing oral tegafur-uracil (UFT) versus classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant therapy in early breast cancer.San AntonioUnited States
2018 Nov 18T. Shimizu2018 Molecular Medicine Conference in PhilippinesOral presentationHarnessing the Power of Precision Medicine – Changing Landscape of Novel Oncology Early Phase 1 Drug Development and Treating Cancers with Implementation of Genome-driven TherapiesManilaPhilippines
2018 Nov 9T. ShimizuThe 2nd CUHK Masterclass in Early Phase Clinical Cancer Research
Hong Kong
Oral presentationPractical Issues and Considerations for Conducting Global First-in-Human Phase 1 TrialsHong KongHKSAR, China
2018 Nov 9S. Kitano2018 Korean Society of Medical Oncology(KSMO) annual meeting Oral presentationKSMO-JSMO joint symposium: Immune-monitoring in JapanSeoulKorea
2018 Oct 27T. ShimizuThe 7th Meeting of Asian National Cancer Centers Alliance (ANCCA)Oral presentationClinical Trials for New Emerging Cancer Drugs - Develop Clinical Trial Unit in Oncology Center- JakartaIndonesia
2018 Oct 22N. YamamotoESMO 2018Poster presentationA Phase 1a/1b study of GDC-0919 (IDO1 inhibitor) as monotherapy and in combination with atezolizumab in Japanese patients (pts) with advanced solid tumorsMunichGermany
2018 Oct 15T. ShimizuPMDA-ATC Pharmaceuticals Review Seminar 2018 in MyanmarOral presentationAccelerating novel oncology drug development in Japan – Current Status and Future Perspectives –Nay Pyi TawMyanmar
2018 Jun 4N. YamamotoASCO 2018Oral presentationErlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567ChicagoUnited States
2018 Jun 1T. ShimizuASCO 2018Oral presentationFirst-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumorsChicagoUnited States
2018 Apr 22S. KitanoThe 7th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC)Oral presentationAnti-PD-1/PD-L1 Antibodies plus Co-Inhibitory Antibodies Taipei Taiwan
2018 Apr 21T. ShimizuThe 7th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC)Oral presentationAnti-PD-1/PD-L1 Antibodies in combination with CSF1R InhibitorsTaipei Taiwan
2018 Apr 6A. ShimomuraGlobal Breast Cancer Conference 2018Poster presentationThe changing landscape of breast cancer patients in oncology early phase I trials for advanced solid tumorsIncheonKorea
2018 Mar 5T. KoyamaTargeted Anticancer Therapies 2018Oral presentationImpact of Chronic Hepatitis Virus Infection on The Feasibility And Efficacy with Hepatocellular Carcinoma in Phase l Clinical Trials for Asian Patients ParisFrance
2018 Mar 5T. EbataTargeted Anticancer Therapies 2018Poster presentationImpact of age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular target agentsParisFrance
2018 Mar 5A. ShimomuraTargeted Anticancer Therapies 2018Poster presentationComparison of model-based dose escalation design with rule-based design of phase I oncology trialsParisFrance
2018 Jan 20T. KoyamaASCO Gastrointestinal Cancers Symposium 2018Poster presentationM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with advanced solid tumorsSun FranciscoUnited States
2018 Jan 18S. IwasaASCO Gastrointestinal Cancers Symposium 2018Poster presentationUpdated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.San FranciscoUnited States
2017 Nov 18T. EbataESMO Asia 2017 CongressPoster presentationPrognostic factors of survival of patients received immunotherapy in phase 1 trialSingaporeSingapore
2017 Nov 18J. SatoESMO Asia 2017 CongressPoster presentationBrain metastases-related microRNAs in the advanced breast cancer patients.SingaporeSingapore
2017 Oct 29T. KoyamaAACR-NCI-EORTC International Conference 2017Poster presentationFirst- in- human phase 1 study of E7090 , a novel selective inhibitors of FGFRs, in patients with advanced solid PhyradelphiaUnited States
2017 Sep 10A. ShimomuraESMO 2017Poster presentationGene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparibMadridSpain
2017 Sep 10N. YamamotoESMO 2017Oral presentationAnti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors.MadridSpain
2017 Jun 23S. KitanoThe 24th Asia Pacific Cancer Conference (APCC)Oral presentationStrategy of Combination ImmunotherapySeoulKorea
2017 May 17J. SatoASCO 2017Publication OnlyStromal infiltrating CD8+ and CD20+ lymphocytes and CD204+ M2 macrophages but not PD-L1 expression on tumor cells are prognosticators for patients with resectable thymic carcinoma ChicagoUnited States
2017 May 17K. SudoASCO 2017Publication OnlySerum microRNAs to predict the response to nivolumab in patients with esophageal squamous cell carcinoma.ChicagoUnited States
2017 Apr 29S. KitanoThe 6th Japan-Taiwan Phase 1 Oncology Conference (JTOPIC)Oral presentationHow to Select the Best Cancer Immunotherapy Combination Trials for Our Patients?Taipei Taiwan
2017 Apr 6T. ShimizuThe 5th US - Japan Clinical Trials in Oncology WorkshopOral presentationChanging of Landscape and New Designs in Early Phase 1 Oncology New Drug Development
−Dual Experiences in Japan/US Phase 1 Centers−
Washington, D.C.United States
2017 Mar 6T. KoyamaTargeted Anticancer Therapies 2017Poster presentationPhase 1 clinical trials for bile duct cancer. ParisFrance
2017 Mar 6K. SudoTargeted Anticancer Therapies 2017Poster presentationTimings of severe toxicity of cytotoxic drugs and molecularly-targeted drugs in phase I trials: a single-institution experience in JapanParisFrance
2017 Mar 6A. ShimomuraTargeted Anticancer Therapies 2017Oral presentationModel-based dose escalation of phase I trials in Japanese patients. – Could it be more efficient than rule-based designs? A single institute experience –ParisFrance
2016 Aug 18T. ShimizuImmuno-Oncology Symposium in TAIWANOral presentationNew Era of Lung Cancer Treatment - How to Adapt I-O Therapy into Clinical Practice –KaohsiungTaiwan